Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul; 30(8):1254-1263.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Glucocorticoids
Glucocorticoids
Humans
Humans
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Prednisone
Prednisone
authors with profiles
Joan Merrill